Announced Wed, 29 Apr · 09:11 IST
Dr. Reddy's gets Health Canada nod for generic Semaglutide Injection
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.7%1-day move
₹1347.40
prior close
₹1367.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.0-2.5-1.9-1.2-1.7-4.4-5.6-2.9-3.0-4.9-2.0-2.0+2.4—
Up moveDown movePending
AI summary
Dr. Reddy's received Health Canada approval (Notice of Compliance) for its generic Semaglutide Injection, used in type 2 diabetes treatment. Dr. Reddy's is the first company to secure marketing authorization for generic Semaglutide in Canada, granted ahead of the review target date. The approval covers 2 mg/pen and 4 mg/pen doses. Canada is the world's second-largest Semaglutide market, with ~3.9 million Canadians living with diagnosed diabetes. API is made in-house.
Likely market impact
Positive — first-mover advantage in Canada's large generic Semaglutide market; strengthens regulated-market diabetes portfolio and revenue potential.